Chloe Bryson-Cahn

Chloe Bryson-Cahn

Auto-generated profile, based on publicly available information

Chloe Bryson-Cahn

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine , Seattle, Washington

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
CBChloe Bryson-Cahn
Chloe Bryson-Cahn
ABAlison M Beieler
Alison M Beieler
JCJeannie D Chan
Jeannie D Chan
RHRobert D Harrington
Robert D Harrington
SDShireesha Dhanireddy
Shireesha Dhanireddy
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.

5 November 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DHDara L Horn
Dara L Horn
EREmma A Roberts
Emma A Roberts
JSJolie Shen
Jolie Shen
JCJeannie D Chan
Jeannie D Chan
EBEileen M Bulger
Eileen M Bulger
BRBryce R H Robinson
Bryce R H Robinson
Background: β-Hemolytic streptococci are frequently implicated in necrotizing soft-tissue infections (NSTIs). Clindamycin administration may improve outcomes in patients with serious streptococcal infections. However, clindamycin resistance is growing worldwide, and resistance patterns in NSTIs and their impact on outcomes are unknown. Methods: Between 2015 and 2018, patients with NSTI at a quaternary referral center were followed up for the outcomes of death, limb loss, and streptococcal toxic shock syndrome. Surgical wound cultures and resistance data were obtained within 48 hours of admission as part of routine care. Risk ratios for the association between these outcomes and the presence of β-hemolytic streptococci or clindamycin-resistant β-hemolytic streptococci were calculated using log-binomial regression, controlling for age, transfer status, and injection drug use–related etiology. Results: Of 445 NSTIs identified, 85% had surgical wound cultures within 48 hours of admission. β-Hemolytic streptococci grew in 31%, and clindamycin resistance was observed in 31% of cultures. The presence of β-hemolytic streptococci was associated with greater risk of amputation (risk ratio, 1.80; 95% confidence interval, 1.07–3.01), as was the presence of clindamycin resistance among β-hemolytic streptococci infections (1.86; 1.10–3.16). Conclusions: β-Hemolytic streptococci are highly prevalent in NSTIs, and in our population clindamycin resistance was more common than previously described. Greater risk of limb loss among patients with β-hemolytic streptococci—particularly clindamycin-resistant strains—may portend a more locally aggressive disease process or may represent preexisting patient characteristics that predispose to both infection and limb loss. Regardless, these findings may inform antibiotic selection and surgical management to maximize the potential for limb salvage.

12 March 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CBChloe Bryson-Cahn
Chloe Bryson-Cahn
JDJeffrey Duchin
Jeffrey Duchin
VMVanessa A Makarewicz
Vanessa A Makarewicz
MKMeagan Kay
Meagan Kay
KRKrista Rietberg
Krista Rietberg
JLJohn B Lynch
John B Lynch
Thousands of people in the United States have required testing for SARS-CoV-2. Evaluation for a special pathogen is resource intensive. We report an innovative approach to home assessment that, in collaboration with public health, enables safe evaluation and specimen collection outside the healthcare setting, avoiding unnecessary exposures and resource utilization.

21 August 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CLCatherine Liu
Catherine Liu
KLKristine Lan
Kristine Lan
EKElizabeth M Krantz
Elizabeth M Krantz
HKH Nina Kim
H Nina Kim
JZJacqlynn Zier
Jacqlynn Zier
ABAndrew Bryan
Andrew Bryan
Inappropriate testing for Clostridioides difficile (C. difficile) leads to overdiagnosis of C. difficile infection (CDI). We determined the effect of a computerized clinical decision support (CCDS) order set on C. difficile PCR test utilization and clinical outcomes. An interrupted time series analysis comparing C. difficile PCR test utilization, hospital-onset CDI rates, and clinical outcomes before and after implementation of a CCDS order set at 2 academic medical centers, University of Washington Medical Center (UWMC) and Harborview Medical Center (HMC). Compared with the 20-month pre-intervention period, during the 12-months post-implementation of the CCDS order set, there was an immediate and sustained reduction in C. difficile PCR test utilization rates at both hospitals (HMC: -28.2%, [95%CI -43.0%, -9.4%], p=.005; UWMC: -27.4%, [95%CI, -37.5%, -15.6%], p &.001). There was a significant reduction in rates of C. difficile tests ordered in the setting of laxatives (HMC: -60.8%, [95%CI -74.3%, -40.1%], p &0.001; UWMC: -37.3%, [95% CI, -58.2%, -5.9%], p=.02). The intervention was associated with an increase in the C. difficile test positivity rate at HMC (p =.01). There were no significant differences HO-CDI rates or in the proportion of patients with HO-CDI who developed severe CDI or CDI-associated complications including ICU transfer, extended length of stay, 30-day mortality, and toxic megacolon. CCDS tools can improve C. difficile diagnostic test stewardship without causing harm. Additional studies are needed to identify key elements of CCDS tools to further optimize C. difficile testing and assess their effect on adverse clinical outcomes.

14 September 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DLDustin R Long
Dustin R Long
VOVikas O’reilly-Shah
Vikas O’reilly-Shah
ARAlison S Rustagi
Alison S Rustagi
CBChloe Bryson-Cahn
Chloe Bryson-Cahn
KJKeith R Jerome
Keith R Jerome
JSJacob E Sunshine
Jacob E Sunshine
Concerns about severe acute respiratory syndrome coronavirus 2 exposure in health care settings may cause patients to delay care. Among 2992 patients testing negative on admission to an academic, 3-hospital system, 8 tested positive during hospitalization or within 14 days postdischarge. Following adjudication of each instance, health care–associated infection incidence ranged from 0.8 to 5.0 cases per 10 000 patient-days.

19 February 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
JHJoanne Huang
Joanne Huang
ZEZahra Kassamali Escobar
Zahra Kassamali Escobar
TBTodd S. Bouchard
Todd S. Bouchard
JLJose Mari G. Lansang
Jose Mari G. Lansang
RJRupali Jain
Rupali Jain
CBChloe Bryson-Cahn
Chloe Bryson-Cahn
The MITIGATE toolkit was developed to assist urgent care and emergency departments in the development of antimicrobial stewardship programs. At the University of Washington, we adopted the MITIGATE toolkit in 10 urgent care centers, 9 primary care clinics, and 1 emergency department. We encountered and overcame challenges: a complex data build, choosing feasible outcomes to measure, issues with accurate coding, and maintaining positive stewardship relationships. Herein, we discuss solutions to challenges we encountered to provide guidance for those considering using this toolkit.